Should I Buy SLDE? SLDE 2026 Analysis

Should You Buy Slide Insurance Holdings Inc (SLDE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

17.130

1 Day change

0.59%

52 Week Range

25.900

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy SLDE now. The setup is attractive despite being near a short-term resistance level: fundamentals are accelerating (2025/Q3 blowout growth), Wall Street targets imply meaningful upside ($21–$22 vs $17.27), and options positioning is strongly risk-on (very low put/call). Near-term price action may chop/pull back, but for an impatient buyer the risk/reward still favors initiating a position ahead of the upcoming earnings catalyst window.

Technical Analysis

Trend/structure: Price is $17.27, pressing into the R2 resistance area (~$17.254) after a +1.79% regular-session move (pre-market -0.60%). This is a short-term ‘at-resistance’ location. Momentum: MACD histogram is slightly negative (-0.0165) but contracting, suggesting downside momentum is fading rather than accelerating. RSI: RSI(6) at ~67.7 is elevated (near overbought), which increases odds of a brief pause or pullback. Moving averages: Converging MAs point to consolidation rather than a strong established trend. Levels: Pivot ~16.376 is the key line to hold; below that, S1 ~15.834. Immediate resistance is ~16.919 then ~17.254 (being tested now). Overall: bullish-to-neutral technically, but entry is not ‘cheap’ today given resistance/RSI.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Strongly bullish skew—puts are very light versus calls both in open interest (0.28) and especially in volume (0.08). Positioning/flow: Today’s options activity is elevated versus normal (today vs 30-day avg volume ~~43x; open interest metrics also elevated), indicating heightened attention. Volatility: 30D IV ~65.83 vs historical vol ~32.76 (rich premium), while IV percentile is low (~~3.9) relative to its own history—net takeaway is options are not signaling panic; traders are leaning upside with limited put demand.

Technical Summary

Sell

Buy

Positive Catalysts

Upcoming earnings/call: Company reports Q4/FY2025 results on Feb 24, 2026 (after close) with a call Feb 25—near-term event catalyst.
Analyst support: Multiple recent price target raises to $21–$22 with Overweight/Outperform ratings.
Business narrative: Tech/AI-driven underwriting and data advantages highlighted in recent coverage, supporting the ‘insurtech efficiency’ thesis.
Options sentiment: Very low put/call ratios suggest traders are positioned for upside or at least not hedging aggressively.

Neutral/Negative Catalysts

with an elevated short-term RSI; higher odds of a near-term dip/consolidation.

Financial Performance

Latest reported quarter: 2025/Q3. Growth: Revenue $265.693M (+32.78% YoY). Profitability surge: Net income $110.997M (+531.49% YoY). Earnings power: EPS $0.79 (+464.29% YoY). Takeaway: Strong acceleration in both top-line and bottom-line results, consistent with improving underwriting/operating leverage—supports a buy thesis into upcoming results.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Clear positive momentum in Street views.

2025-11-17 Morgan Stanley: Overweight, PT raised to $21 from $18.
2025-11-06 Piper Sandler: Overweight, PT raised to $21 from $18 (called underwriting better than expected).
2025-11-06 Keefe Bruyette: Outperform, PT raised to $22 from $19. Wall Street pros: Strong underwriting results, improving model updates, and meaningful upside to targets. Wall Street cons: Cycle softening risk into 2026 (potential pressure on pricing and growth rates).

4 Analyst Rating

Wall Street analysts forecast SLDE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLDE is 22.25 USD with a low forecast of 21 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 17.030

Low

Averages

22.25

High

Current: 17.030

Low

Averages

22.25

High

Morgan Stanley

NULL -> Overweight

maintain

$18 -> $21

AI Analysis

2025-11-17

Reason

Morgan Stanley

Price Target

$18 -> $21

AI Analysis

2025-11-17

maintain

NULL -> Overweight

Reason

Morgan Stanley raised the firm's price target on Slide Insurance to $21 from $18 and keeps an Overweight rating on the shares. The firm updated models in the insurance space post the Q3 reports. For property and casualty, Morgan Stanley sees a softening cycle heading into 2026, the analyst tells investors.

Piper Sandler

Overweight

maintain

$18 -> $21

2025-11-06

Reason

Piper Sandler

Price Target

$18 -> $21

2025-11-06

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Slide Insurance to $21 from $18 and keeps an Overweight rating on the shares following quarterly results. The firm says underlying underwriting results were better than it expected. Piper thinks Slide had a solid quarter.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SLDE

Unlock Now

SLDE Should I Buy

SLDE Should I Buy

Should You Buy Slide Insurance Holdings Inc (SLDE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch